Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 1,026-1,050 of 3,186
RecruitingNCT05895383

Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

This observational study is following people with Procedural Pain, Pain Catastrophizing, or Procedural Anxiety to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

AnxietyOtherFrom 21 Years to 85 Years
Countries
United States
Sponsor
Beth Israel Deaconess Medical Center
Condition
Anxiety
RecruitingNCT05064813

MBSR Mechanisms in GAD

This study is looking at whether a digital support tool can help people with Generalized anxiety. Participants take part in a digital support tool and complete follow-up assessments.

AnxietyOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
NYU Langone Health
Condition
Anxiety
RecruitingNCT07391020

Text Message Safety Behavior Fading for Pathological Worry

This study is looking at whether Safety Behavior Fading for Pathological Worry can help people with Generalized anxiety, Worrying, or Anxiety. Participants take part in Safety Behavior Fading for Pathological Worry and complete follow-up assessments.

AnxietyOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Florida State University
Condition
Anxiety
Not Yet RecruitingNCT07390487

The Effects of Audio-Based Therapy on Anxiety in Psoriasis

This study is looking at evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms for people with Psoriasis or Anxiety. Participants take part in a digital support tool and complete follow-up assessments.

AnxietyOtherOver 18 Years
Countries
United States
Sponsor
University of California, San Francisco
Condition
Anxiety
RecruitingNCT06595953

Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

This study is comparing Gaze-Contingent Music Reward Therapy with Sham-GCMRT for people with anxiety. Participants receive Gaze-Contingent Music Reward Therapy or Sham-GCMRT and complete study visits and assessments.

AnxietyOtherFrom 8 Years to 17 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Anxiety
RecruitingNCT06809179

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

This study is comparing Fasedienol Nasal Spray - Placebo Nasal Spray with placebo for people with Social anxiety. Participants receive Fasedienol Nasal Spray - Placebo Nasal Spray or placebo and complete study visits and assessments.

AnxietyOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
VistaGen Therapeutics, Inc.
Condition
Anxiety
RecruitingNCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

This study is looking at care and outcomes for people with Schizophrenia or Autism-Related Irritability. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 5 Years to 17 Years
Countries
Canada, France, Germany, Hungary, Japan, Poland, Romania, Spain, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07410507

A Study of Brenipatide in Adult Participants With Schizophrenia

This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Argentina, Brazil, China, India, Japan, Taiwan, United States
Sponsor
Eli Lilly and Company
Condition
Schizophrenia
RecruitingNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

This study is looking at how safe and effective KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD is for people with Alzheimer Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Not Yet RecruitingNCT07488156

Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder

This study is looking at whether questionnaires and follow-up can help people with Schizophrenia Disorder, schizoaffective disorder, or Psychosis. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Condition
Schizophrenia
RecruitingNCT06774417

Digital Strategies to Advance Help-Seeking - Aim 3

This study is looking at whether a digital support tool can help people with Clinical High Risk, Early Psychosis, or First Episode Psychosis. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.

SchizophreniaOtherFrom 12 Years to 29 Years
Countries
United States
Sponsor
Columbia University
Condition
Schizophrenia
RecruitingNCT07467993

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

This study is looking at assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Novartis Pharmaceuticals
Condition
Schizophrenia
RecruitingNCT07483294

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

This study is looking at investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis for people with Psychosis or Acute. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 16 Years to 40 Years
Countries
United States
Sponsor
Northwell Health
Condition
Schizophrenia
RecruitingNCT05770375

Tolerability of MDMA in Schizophrenia

This study is looking at whether MDMA 40mg can help people with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Anya Bershad, MD, PhD
Condition
Schizophrenia
RecruitingNCT05304767

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This study is looking at whether Xanomeline and Trospium Chloride Capsules can help people with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Bulgaria, Czech Republic, India, Japan, Poland, Romania, Serbia, United Kingdom, United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
RecruitingNCT07221877

A Study to Evaluate the Effect of KarXT on Urological Safety

This study is looking at characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia. Taking part may give some people access to Xanomeline/trospium chloride, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Bristol-Myers Squibb
Condition
Schizophrenia
Active Not RecruitingNCT00001246

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

This observational study is following people with Attention Deficit Hyperactivity Disorder, Schizophrenia, or Attention Deficit Disorder With Hyperactivity to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.

SchizophreniaOtherFrom 3 Years to 120 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
RecruitingNCT07459647

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

This observational study is following people with Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
MapLight Therapeutics
Condition
Schizophrenia
RecruitingNCT07460453

Racial Disparities in the Expression of Paranoia

This study is looking at whether a digital support tool can help people with Paranoia or psychosis. Participants take part in a digital support tool and complete follow-up assessments.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Indiana University
Condition
Schizophrenia
RecruitingNCT06944847

Vaping and Smoking Project in People With Schizophrenia

This study is looking at whether Acute (24-hour) abstinence can help people with Acute Abstinence From Cigarettes vs E-cigarettes. Participants take part in Acute (24-hour) abstinence and complete follow-up assessments.

SchizophreniaOtherFrom 21 Years to 50 Years
Countries
United States
Sponsor
State University of New York at Buffalo
Condition
Schizophrenia